S49076, a multi-kinase MET, AXL, and MERTK inhibitor, in combination with bevacizumab was also well tolerated in glioblastoma patients (ISRCTN11619481) in phase I/II study [120]. This evidence concerns the gene MERTK and glioblastoma.